26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. - Evidence Based Medicine on FHIR Implementation Guide v2.0.0-ballot

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Citation: 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Active as of 2024-12-19

Generated Narrative: Citation 179621

version: 8; Last updated: 2024-11-22 19:27:42+0000

Profile: JournalArticleCitation

url: Citation 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

identifier: FEvIR Object Identifier/https://fevir.net/FOI/179621, https://pubmed.ncbi.nlm.nih.gov/26028518, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.7

version: 2.0.0-ballot

title: 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

status: Active

date: 2024-12-19 14:29:51+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

Code

Value[x]

Citation Classification Type fevir-platform-use: FEvIR Platform Use

Medline Base

jurisdiction: World

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2015-09-28

lastReviewDate: 2024-08-05

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification
type: Citation Source
classifier: MEDLINE

classification
type: MEDLINE Citation Owner
classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate
activity: PubMed Pubstatus of Received
period: ?? --> 2015-04-15

statusDate
activity: PubMed Pubstatus of Revised
period: ?? --> 2015-05-06

statusDate
activity: PubMed Pubstatus of Accepted
period: ?? --> 2015-05-08

statusDate
activity: PubMed Pubstatus of Entrez
period: ?? --> 2015-06-02 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Pubmed
period: ?? --> 2015-06-02 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Medline
period: ?? --> 2015-09-29 06:00:00+0000

citedArtifact
identifier: https://pubmed.ncbi.nlm.nih.gov/26028518, https://doi.org/10.1016/S1470-2045(15)00011-X, pii/S1470-2045(15)00011-X
relatedIdentifier: https://clinicaltrials.gov/NCT00055731
Titles
- Type Language Text
* Primary title English
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Abstracts
- Text Copyright
*
BACKGROUND: Early risk-stratified chemotherapy is a standard treatment for breast, colorectal, and lung cancers, but not for high-risk localised prostate cancer. Combined docetaxel and estramustine improves survival in patients with castration-resistant prostate cancer. We assessed the effects of combined docetaxel and estramustine on relapse in patients with high-risk localised prostate cancer. METHODS: We did this randomised phase 3 trial at 26 hospitals in France. We enrolled patients with treatment-naive prostate cancer and at least one risk factor (ie, stage T3-T4 disease, Gleason score of ≥8, prostate-specific antigen concentration >20 ng/mL, or pathological node-positive). All patients underwent a staging pelvic lymph node dissection. Patients were randomly assigned (1:1) to either androgen deprivation therapy (ADT; goserelin 10·8 mg every 3 months for 3 years) plus four cycles of docetaxel on day 2 at a dose of 70 mg/m(2) and estramustine 10 mg/kg per day on days 1-5, every 3 weeks, or ADT only. The randomisation was done centrally by computer, stratified by risk factor. Local treatment was administered at 3 months. Neither patients nor investigators were masked to treatment allocation. The primary endpoint was relapse-free survival in the intention-to-treat population. Follow-up for other endpoints is ongoing. This study is registered with ClinicalTrials.gov, number NCT00055731. FINDINGS: We randomly assigned 207 patients to the ADT plus docetaxel and estramustine group and 206 to the ADT only group. Median follow-up was 8·8 years (IQR 8·1-9·7). 88 (43%) of 207 patients in the ADT plus docetaxel and estramustine group had an event (relapse or death) versus 111 (54%) of 206 in the ADT only group. 8-year relapse-free survival was 62% (95% CI 55-69) in the ADT plus docetaxel and estramustine group versus 50% (44-57) in the ADT only group (adjusted hazard ratio [HR] 0·71, 95% CI 0·54-0·94, p=0·017). Of patients who were treated with radiotherapy and had data available, 31 (21%) of 151 in the ADT plus docetaxel and estramustine group versus 26 (18%) of 143 in the ADT only group reported a grade 2 or higher long-term side-effect (p=0·61). We recorded no excess second cancers (26 [13%] of 207 vs 22 [11%] of 206; p=0·57), and there were no treatment-related deaths. INTERPRETATION: Docetaxel-based chemotherapy improves relapse-free survival in patients with high-risk localised prostate cancer. Longer follow-up is needed to assess whether this benefit translates into improved metastasis-free survival and overall survival. FUNDING: Ligue Contre le Cancer, Sanofi-Aventis, AstraZeneca, Institut National du Cancer.

Copyright © 2015 Elsevier Ltd. All rights reserved.

relatesTo
type: comment-in
classifier: Comment
citation:
Lancet Oncol. 2015 Jul;16(7):741-2. doi: 10.1016/S1470-2045(15)00012-1

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/26028517/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26028517
relatesTo
type: comment-in
classifier: Comment
citation:
Nat Rev Urol. 2015 Jul;12(7):358. doi: 10.1038/nrurol.2015.146

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/26077993/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26077993
relatesTo
type: comment-in
classifier: Comment
citation:
Eur Urol. 2015 Dec;68(6):1098-9. doi: 10.1016/j.eururo.2015.08.047

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/26545569/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26545569
relatesTo
type: comment-in
classifier: Comment
citation:
Nat Rev Clin Oncol. 2015 Dec;12(12):687-8. doi: 10.1038/nrclinonc.2015.192

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/26552950/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26552950
publicationForm
publishedIn
type: Periodical
identifier: Electronic ISSN Type/1474-5488, ISOAbbreviation/Lancet Oncol, ISSN Linking/1470-2045, Medline Title Abbreviation/Lancet Oncol, NLM Unique ID/100957246
title: The Lancet. Oncology
publisherLocation: England
citedMedium: Internet
volume: 16
issue: 7
articleDate: 2015-07
publicationDateText: 2015-Jul
language: English
pageString: 787-94
publicationForm
citedMedium: Internet without issue
articleDate: 2015-05-28
webLocation
classifier: Abstract
url: https://pubmed.ncbi.nlm.nih.gov/26028518/
webLocation
classifier: DOI Based
url: https://doi.org/10.1016/S1470-2045(15)00011-X
classification
type: Publishing Model
classifier: Print Electronic
classification
type: Chemical
classifier: Androgen Antagonists, Taxoids, Docetaxel, Estramustine, Prostate-Specific Antigen
classification
type: MeSH heading
artifactAssessment: ArtifactAssessment: artifact[x] = this resource
classification
type: Publication type
classifier: Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
classification
type: Knowledge Artifact Type
classifier: Journal Article
artifactAssessment: Classifier added by Computable Publishing LLC
classification
type: Citation subset
classifier: IM
contributorship
complete: true
entry
contributor: Fizazi K
forenameInitials: K
affiliation: Institut Gustave Roussy, Villejuif, France. Electronic address: karim.fizazi@gustaveroussy.fr.
entry
contributor: Faivre L
forenameInitials: L
affiliation: Institut Gustave Roussy, Villejuif, France.
entry
contributor: Lesaunier F
forenameInitials: F
affiliation: Centre François Baclesse, Caen, France.
entry
contributor: Delva R
forenameInitials: R
affiliation: Institut de Cancérologie de l'Ouest, Angers, France.
entry
contributor: Gravis G
forenameInitials: G
affiliation: Institut Paoli Calmettes, Marseille, France.
entry
contributor: Rolland F
forenameInitials: F
affiliation: Institut de Cancérologie de l'Ouest, Nantes, France.
entry
contributor: Priou F
forenameInitials: F
affiliation: Centre Hospitalier Départemental, La Roche-sur-Yon, France.
entry
contributor: Ferrero JM
forenameInitials: JM
affiliation: Centre Antoine Lacassagne, Nice, France.
entry
contributor: Houede N
forenameInitials: N
affiliation: Centre Hospitalier de Nimes, Nimes, France.
entry
contributor: Mourey L
forenameInitials: L
affiliation: Institut Claudius Regaud, Toulouse, France.
entry
contributor: Theodore C
forenameInitials: C
affiliation: Hôpital Foch, Paris, France.
entry
contributor: Krakowski I
forenameInitials: I
affiliation: Centre Alexis Vautrin, Nancy, France.
entry
contributor: Berdah JF
forenameInitials: JF
affiliation: Clinique Sainte-Marguerite, Hyères, France.
entry
contributor: Baciuchka M
forenameInitials: M
affiliation: Centre Hospitalier La Timone, Marseille, France.
entry
contributor: Laguerre B
forenameInitials: B
affiliation: Centre Eugène Marquis, Rennes, France.
entry
contributor: Fléchon A
forenameInitials: A
affiliation: Centre Léon Bérard, Lyon, France.
entry
contributor: Ravaud A
forenameInitials: A
affiliation: Hôpital Saint-André, Bordeaux, France.
entry
contributor: Cojean-Zelek I
forenameInitials: I
affiliation: Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.
entry
contributor: Oudard S
forenameInitials: S
affiliation: Hôpital Européen Georges Pompidou, Paris, France.
entry
contributor: Labourey JL
forenameInitials: JL
affiliation: CHU Dupuytren, Limoges, France.
entry
contributor: Chinet-Charrot P
forenameInitials: P
affiliation: Centre Henri Becquerel, Rouen, France.
entry
contributor: Legouffe E
forenameInitials: E
affiliation: Centre Médical Oncogard, Nimes, France.
entry
contributor: Lagrange JL
forenameInitials: JL
affiliation: Hôpital Henri-Mondor, Créteil, France.
entry
contributor: Linassier C
forenameInitials: C
affiliation: Hôpital Bretonneau, Tours, France.
entry
contributor: Deplanque G
forenameInitials: G
affiliation: Hôpital Saint-Joseph, Paris, France.
entry
contributor: Beuzeboc P
forenameInitials: P
affiliation: Institut Curie, Paris, France.
entry
contributor: Davin JL
forenameInitials: JL
affiliation: Clinique Sainte-Catherine, Avignon, France.
entry
contributor: Martin AL
forenameInitials: AL
affiliation: Unicancer, Paris, France.
entry
contributor: Habibian M
forenameInitials: M
affiliation: Unicancer, Paris, France.
entry
contributor: Laplanche A
forenameInitials: A
affiliation: Institut Gustave Roussy, Villejuif, France.
entry
contributor: Culine S
forenameInitials: S
affiliation: Hôpital Saint-Louis, Paris, France.

Generated Narrative: Practitioner #contributor0

name: Karim Fizazi

Generated Narrative: Practitioner #contributor1

name: Laura Faivre

Generated Narrative: Practitioner #contributor2

name: François Lesaunier

Generated Narrative: Practitioner #contributor3

name: Remy Delva

Generated Narrative: Practitioner #contributor4

name: Gwenaëlle Gravis

Generated Narrative: Practitioner #contributor5

name: Frédéric Rolland

Generated Narrative: Practitioner #contributor6

name: Frank Priou

Generated Narrative: Practitioner #contributor7

name: Jean-Marc Ferrero

Generated Narrative: Practitioner #contributor8

name: Nadine Houede

Generated Narrative: Practitioner #contributor9

name: Loïc Mourey

Generated Narrative: Practitioner #contributor10

name: Christine Theodore

Generated Narrative: Practitioner #contributor11

name: Ivan Krakowski

Generated Narrative: Practitioner #contributor12

name: Jean-François Berdah

Generated Narrative: Practitioner #contributor13

name: Marjorie Baciuchka

Generated Narrative: Practitioner #contributor14

name: Brigitte Laguerre

Generated Narrative: Practitioner #contributor15

name: Aude Fléchon

Generated Narrative: Practitioner #contributor16

name: Alain Ravaud

Generated Narrative: Practitioner #contributor17

name: Isabelle Cojean-Zelek

Generated Narrative: Practitioner #contributor18

name: Stéphane Oudard

Generated Narrative: Practitioner #contributor19

name: Jean-Luc Labourey

Generated Narrative: Practitioner #contributor20

name: Paule Chinet-Charrot

Generated Narrative: Practitioner #contributor21

name: Eric Legouffe

Generated Narrative: Practitioner #contributor22

name: Jean-Léon Lagrange

Generated Narrative: Practitioner #contributor23

name: Claude Linassier

Generated Narrative: Practitioner #contributor24

name: Gaël Deplanque

Generated Narrative: Practitioner #contributor25

name: Philippe Beuzeboc

Generated Narrative: Practitioner #contributor26

name: Jean-Louis Davin

Generated Narrative: Practitioner #contributor27

name: Anne-Laure Martin

Generated Narrative: Practitioner #contributor28

name: Muriel Habibian

Generated Narrative: Practitioner #contributor29

name: Agnès Laplanche

Generated Narrative: Practitioner #contributor30

name: Stéphane Culine

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
content
type: components (if present) include qualifier codings
classifier: Aged
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Androgen Antagonists
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic Yes
content
type: components (if present) include qualifier codings
classifier: Antineoplastic Combined Chemotherapy Protocols
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic Yes
content
type: components (if present) include qualifier codings
classifier: Disease-Free Survival
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Docetaxel
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Dose-Response Relationship, Drug
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Drug Administration Schedule
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Estramustine
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: Follow-Up Studies
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: France
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Humans
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Kaplan-Meier Estimate
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Male
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Maximum Tolerated Dose
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Middle Aged
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Neoplasm Invasiveness
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: pathology
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: Neoplasm Recurrence, Local
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: epidemiology
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: pathology
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: Neoplasm Staging
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Proportional Hazards Models
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Prostate-Specific Antigen
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: blood
Components
- Type Classifier
* is Major topic Yes
content
type: components (if present) include qualifier codings
classifier: Prostatic Neoplasms
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug therapy
Components
- Type Classifier
* is Major topic Yes
component
type: qualifier
classifier: mortality
Components
- Type Classifier
* is Major topic Yes
component
type: qualifier
classifier: pathology
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: Survival Analysis
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Taxoids
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: Treatment Outcome
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic